{"chunk_type":"transcript_chunk","text":"# Bleeding Patient Framework: Platelets vs Coagulation Factors\n## Core split\n- Primary hemostasis (platelet) defects -> mucosal bleeding, petechiae, epistaxis.\n- Secondary hemostasis (factor) defects -> deep tissue bleeding, hemarthrosis.\n\n## Platelet-count reduction approach\n1. Decreased production: marrow suppression, viral etiologies (including HIV/HCV), alcohol/toxins, nutrient deficiency.\n2. Increased destruction/consumption: immune causes (ITP/HIT), MAHA spectrum (TTP/HUS/DIC).\n3. Sequestration: splenomegaly-related pooling.\n\n## Practical table\n| Clue pattern | Most likely branch | Immediate implication |\n| --- | --- | --- |\n| petechiae + mucosal ooze | platelet disorder | evaluate count/function and destruction causes |\n| hemarthrosis/deep hematoma | factor pathway disorder | coagulation testing + mixing logic |\n\n## Initial high-yield warnings\n- Interpret thrombocytopenia through production vs destruction vs sequestration.\n- Use mixing studies to distinguish deficiency from inhibitor when PT/PTT are prolonged.\n- TTP and HUS management errors are high-risk (platelets in TTP, antibiotics in Shiga-HUS).","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-103","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","treatment"]}
{"chunk_type":"transcript_chunk","text":"# Pseudothrombocytopenia, Mixing Study Logic, and Vitamin K Deficiency\n## Pseudothrombocytopenia trap\n- EDTA-dependent platelet clumping can produce falsely low automated counts.\n- Confirm with citrate/heparin tube repeat CBC and peripheral smear review.\n\n## Mixing study decision rule\n| Mixing result | Interpretation | Typical examples |\n| --- | --- | --- |\n| Corrects | factor deficiency | hemophilia, vitamin K deficiency |\n| Fails to correct | inhibitor present | lupus anticoagulant, factor inhibitors |\n\n## Vitamin K deficiency\n- Affects factors II, VII, IX, X and proteins C/S.\n- PT/INR often rises early (factor VII short half-life).\n\n## Clinical contexts\n- Newborn bleeding without prophylaxis: prevent with IM vitamin K at birth.\n- Prolonged broad-spectrum antibiotics or severe malnutrition/cholestatic states can precipitate deficiency.\n- Active significant bleeding may require factor replacement support in addition to vitamin K.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-123","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"# ITP and TTP Core Pathways\n## Immune thrombocytopenia (ITP)\n- Autoantibody-mediated platelet clearance (often GP IIb/IIIa-target pattern) via splenic macrophages.\n- Typical profile: isolated thrombocytopenia with otherwise preserved cell lines/coagulation tests.\n- Adults require HIV and hepatitis C exclusion.\n\n## ITP management principles\n- Children with mild cutaneous-only bleeding: often observation.\n- Treatment threshold generally lower platelets or clinically relevant bleeding.\n- Options: corticosteroids, IVIG; refractory courses may require rituximab or splenectomy pathway.\n\n## TTP pathophysiology\n- Severe ADAMTS13 deficiency -> ultra-large vWF multimers -> platelet-rich microthrombi and MAHA.\n- Lab pattern: schistocytes, hemolysis markers, thrombocytopenia, usually normal PT/PTT.\n\n## TTP clinical signature\n- Neurologic findings are often prominent; renal involvement variable.\n- Classic pentad may be incomplete in real presentation.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-143","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","mnemonic"]}
{"chunk_type":"transcript_chunk","text":"# TTP vs HUS: Emergency Management Differences\n## TTP treatment\n- Immediate plasma exchange is life-saving and should not be delayed.\n- Platelet transfusion is generally contraindicated unless exceptional life-threatening bleeding context is explicitly directed by specialists.\n\n## HUS profile\n- Typical pediatric post-diarrheal course after Shiga-toxin-producing E. coli exposure.\n- MAHA + thrombocytopenia + dominant acute kidney injury pattern.\n\n## HUS treatment\n- Primarily supportive: fluid/electrolyte management and renal support/dialysis as needed.\n- Avoid routine antibiotics and antimotility agents in classic STEC-HUS setting due to toxin-related worsening risk.\n\n## TTP-HUS differentiation pearl\n- TTP: neurologic prominence and ADAMTS13-mediated mechanism.\n- HUS: renal predominance after bloody diarrheal prodrome.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-163","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","treatment","pathophysiology"]}
{"chunk_type":"recap_summary","text":"# Rapid Recap: Platelet and Hemostasis Emergencies\n| Condition | Mechanism | Key clue | Next step |\n| --- | --- | --- | --- |\n| Pseudothrombocytopenia | in-vitro clumping artifact | severe low count but discordant clinical picture | repeat count in citrate/heparin tube |\n| Vitamin K deficiency | reduced gamma-carboxylated factors | newborn bleed or prolonged antibiotics/cholestasis | vitamin K ± factor support for major bleeding |\n| ITP | immune platelet destruction | isolated thrombocytopenia | observe vs steroid/IVIG by bleeding risk |\n| TTP | ADAMTS13 deficiency MAHA | neuro signs + schistocytes + low platelets | urgent plasma exchange, avoid platelets |\n| HUS | shiga-toxin microangiopathy | bloody diarrhea followed by AKI | supportive care, avoid antibiotics/antimotility |\n| Prolonged PT/PTT workup | deficiency vs inhibitor | mixing study branch point | correction=deficiency, no correction=inhibitor |\n\n## Extra exam pearls\n- TTP usually has normal coagulation times unlike overt DIC.\n- Splenic sequestration can explain low platelets in portal hypertension with limited bleeding phenotype.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-174","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","recap","diagnosis","treatment","pathophysiology","mnemonic"]}
{"chunk_type":"transcript_chunk","text":"# Hemostasis Disorders: Consolidated Classification\n## Primary hemostasis branch\n- Platelet number defects: immune destruction, MAHA consumption, sequestration.\n- Platelet function defects: vWD, uremic dysfunction, antiplatelet drug effect.\n\n## Secondary hemostasis branch\n- Factor deficiencies: hemophilia/Vitamin K–dependent factor deficits.\n- Factor inhibitors: lupus anticoagulant or acquired inhibitor states.\n\n## Clinical pattern rules\n| Pattern | Typical disorder type |\n| --- | --- |\n| mucosal/petechial bleeding | platelet plug problem |\n| deep tissue/joint bleeding | coagulation factor problem |\n\n## Systems-level framing\n- Hemostasis failure can manifest as thrombosis or bleeding depending on where the pathway is overactive vs exhausted.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-184","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"# MAHA Mechanisms, TTP, HUS, and ITP (Integrated)\n## MAHA concept\n- Microvascular thrombi shear RBCs -> schistocytes + hemolytic anemia + thrombocytopenia.\n\n## TTP\n- Ultra-large vWF multimers from ADAMTS13 failure drive platelet-rich microthrombi.\n- Management: urgent plasma exchange; avoid platelet transfusion in standard presentation.\n\n## HUS\n- Shiga toxin-associated endothelial injury with kidney-predominant microangiopathy.\n- Management: supportive care; avoid routine antibiotics/antidiarrheals in classic post-diarrheal cases.\n\n## ITP\n- Isolated immune thrombocytopenia with normal coagulation profile.\n- HIV/HCV testing is a required exclusion step in adults.\n- Treat based on bleeding severity/platelet thresholds, not count alone in every case.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-204","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"# ITP, Mixing Studies, Lupus Anticoagulant, and DIC\n## ITP therapeutic logic\n- Observation is appropriate for stable higher-count patients without significant bleeding.\n- Steroids and IVIG are standard first-line options when treatment criteria are met.\n\n## Factor deficiency vs inhibitor by mixing test\n| Scenario | Mixing outcome | Interpretation |\n| --- | --- | --- |\n| Hemophilia/factor deficiency | correction | missing factor replaced |\n| Inhibitor state | no correction | inhibitor neutralizes added normal plasma |\n\n## Lupus anticoagulant paradox\n- Can prolong PTT in vitro while clinical phenotype is thrombotic tendency (APS context).\n\n## DIC summary\n- Consumptive coagulopathy where platelets/factors/fibrinogen are depleted.\n- Acute DIC often bleeding-dominant; chronic DIC in malignancy may appear thrombosis-predominant.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-224","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment"]}
{"chunk_type":"transcript_chunk","text":"# DIC, Vitamin K, and Anticoagulant Reversal Toolkit\n## DIC phenotypes\n| Type | Typical trigger | Predominant manifestation |\n| --- | --- | --- |\n| Acute DIC | sepsis, trauma, obstetric catastrophe | diffuse bleeding/oozing |\n| Chronic DIC | malignancy-associated drivers | recurrent thrombosis tendency |\n\n## Vitamin K physiology reminder\n- Factor dependence: II, VII, IX, X plus proteins C/S.\n- Gut flora disruption can worsen deficiency in prolonged antibiotic exposure.\n\n## Reversal table\n| Agent | Reversal strategy | High-yield note |\n| --- | --- | --- |\n| Warfarin major bleed | PCC + IV vitamin K | PCC works immediately; vitamin K sustains correction |\n| Unfractionated heparin | protamine sulfate | dose-dependent neutralization |\n| Selected DOACs | specific antidotes (idarucizumab/andexanet context) | agent-specific application |\n| Antiplatelet severe bleed | platelet support in selected severe cases | decision individualized by urgency/context |","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-244","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","pathophysiology"]}
{"chunk_type":"recap_summary","text":"# Rapid Recap: MAHA, ITP, Mixing, and Reversal\n- Schistocytes suggest MAHA branch (TTP/HUS/DIC context).\n- TTP treatment priority is plasma exchange; avoid routine platelet transfusion.\n- Child with bloody diarrhea then AKI suggests HUS; supportive management and avoid routine antibiotics.\n- Isolated thrombocytopenia should trigger ITP pathway plus HIV/HCV exclusion.\n- Mixing test that corrects indicates deficiency; no correction indicates inhibitor.\n- In urgent warfarin-associated major bleeding, PCC-based rapid factor restoration is central.\n\n## Transition note\n- Next section introduces Hodgkin survivorship and oncology treatment-related late effects; non-learning conversational lines removed.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-254","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","recap","treatment"]}
{"chunk_type":"transcript_chunk","text":"# Oncology Complications Framework: Acute vs Late Effects\n## Time-course structure\n```\nCancer-therapy complications\n├── Acute emergencies\n│   ├── Tumor lysis syndrome\n│   └── Neutropenic/infectious complications\n└── Late survivorship effects\n    ├── Secondary malignancies\n    ├── Cardiovascular toxicity\n    └── Endocrine/pulmonary sequelae\n```\n\n## Hodgkin survivor doorway scenario logic\n- Long-interval survivors with new cardiopulmonary symptoms require late-effect workup before assuming simple relapse.\n- Risk attribution changes by years since treatment.\n\n## Late-effect high-yield table\n| Treatment exposure | Typical late risk |\n| --- | --- |\n| chest/field radiation | secondary solid tumors, CAD/valvular/pericardial fibrosis patterns |\n| anthracycline chemotherapy | dose-related dilated cardiomyopathy risk |\n\n## Practical next step\n- Evaluate both pulmonary and cardiac causes (imaging + echocardiography as indicated).","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-264","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","treatment","pathophysiology","tree"]}
{"chunk_type":"transcript_chunk","text":"# Hodgkin Survivorship, Cardiotoxicity, TLS, and Imaging Pitfalls\n## Survivorship risk transition\n- Early years after therapy: relapse concern remains meaningful.\n- Long-latency phase: secondary malignancy and treatment-related cardiovascular disease dominate mortality burden.\n\n## Cardiotoxicity distinction\n- Radiation exposure: restrictive/pericardial/valvular/CAD fibrotic patterns.\n- Anthracyclines: dilated cardiomyopathy pattern, cumulative-dose concern.\n\n## Multiple myeloma imaging trap\n- Bone scan can miss lytic-only disease due to low osteoblastic activity.\n- Preferred modalities: skeletal survey or low-dose whole-body CT.\n\n## Tumor lysis syndrome essentials\n- Hyperkalemia, hyperphosphatemia, hyperuricemia with AKI risk after rapid tumor breakdown.\n- Prevention/treatment pathways include uric-acid control and aggressive supportive management.\n- Rasburicase caution in G6PD deficiency due to oxidative hemolysis risk.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-284","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology"]}
{"chunk_type":"recap_summary","text":"# Rapid Recap: Survivorship and Hematology Crisis Management\n| Clinical scenario | Key mechanism | Next-step anchor |\n| --- | --- | --- |\n| Hodgkin survivor decades later with new chest symptoms | late secondary cancer/cardiotoxicity risk | targeted cancer screening + cardiac evaluation |\n| Prior anthracycline exposure with HF pattern | chemotherapy cardiomyopathy | echocardiographic assessment and HF-guided management |\n| Radiation history with restrictive/pericardial features | fibrosis-mediated heart disease | cardiology-directed structural evaluation |\n| Myeloma suspicion with bone pain | lytic process | skeletal survey/whole-body CT, not bone scan alone |\n| TLS patient receiving uric-acid therapy with hemolysis signs | possible G6PD-sensitive oxidative injury | stop offending therapy and treat hemolysis supportively |\n| Major anticoagulation bleed | drug-specific reversal urgency | apply rapid reversal protocol by anticoagulant class |\n\n## Cleanup\n- Removed quiz invitations and non-learning narrative; retained high-yield clinical actions only.","subject":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","page_title":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","episode":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","section_path":["LM_Blood2 2fd46f2986ee8009895af4ea339219a2"],"source_doc_id":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","source_page":null,"source_anchor":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2-296","focus_area":"LM_Blood2 2fd46f2986ee8009895af4ea339219a2","tags":["usmle-step2","core","recap","diagnosis","treatment","pathophysiology"]}
